comparemela.com
Home
Live Updates
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study
Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study
<iframe src=https://www.youtube.com/embed/XRlhyHSAEaA></iframe>Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary... | June 5, 2023
Related Keywords
Canada ,
Christopher Moreau ,
Algernon Pharmaceuticals ,
Algernon Neuroscience ,
Algernon Pharmaceuticals Inc Stock Exchange ,
News ,
Information ,
Press Release ,
Pharmaceuticals ,
Ceo ,
Christopher ,
Moreau ,
Oined ,
Steve ,
Darling ,
Rom ,
Proactive ,
O ,
Rovide ,
N ,
Update ,
N Agn Ca01559r4008 ,